MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.
Frontiers In Oncology
Eleveld, Thomas F TF; Vernooij, Lindy L; Schild, Linda L; Koopmans, Bianca B; Alles, Lindy K LK; Ebus, Marli E ME; Dandis, Rana R; van Tinteren, Harm H; Caron, Huib N HN; Koster, Jan J; van Noesel, Max M MM; Tytgat, Godelieve A M GAM; Eising, Selma S; Versteeg, Rogier R; Dolman, M Emmy M MEM; Molenaar, Jan J JJ
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions.
Cancers
Zaremba, Anne A; Jansen, Philipp P; Murali, Rajmohan R; Mayakonda, Anand A; Riedel, Anna A; Krahl, Dieter D; Burkhardt, Hans H; John, Stefan S; Géraud, Cyrill C; Philip, Manuel M; Kretz, Julia J; Möller, Inga I; Stadtler, Nadine N; Sucker, Antje A; Paschen, Annette A; Ugurel, Selma S; Zimmer, Lisa L; Livingstone, Elisabeth E; Horn, Susanne S; Plass, Christoph C; Schadendorf, Dirk D; Hadaschik, Eva E; Lutsik, Pavlo P; Griewank, Klaus K
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Bmc Cancer
Heppt, Markus V MV; Siepmann, Timo T; Engel, Jutta J; Schubert-Fritschle, Gabriele G; Eckel, Renate R; Mirlach, Laura L; Kirchner, Thomas T; Jung, Andreas A; Gesierich, Anja A; Ruzicka, Thomas T; Flaig, Michael J MJ; Berking, Carola C